How many patents does
Raqualia Pharma have?
patents
594
families
49
granted
129
applications
465
EP
81
US
80
CN
55
JP
47
WO
34
KR
33
RoW
264
Buy the report
The report contains ten-year analysis with the following sections
- patent filing analysis
- worldwide filing analysis
- patent family analysis
- application analysis
- granted analysis
- classification analysis
- citation analysis
contact us for pricing
- VAT will apply to UK companies
- EU companies must supply their VAT number
Check out our sample pages |
Find companies to compare
Many companies now available
companies
12,000+
patents
42 million
patent families
23 million
Search to find companies of interest
read summary of their published patent
the following tables are just extracts from the report
the company report contains more information
Raqualia Pharma
Top ten assignees appearing on patents
2009 - 2018
| raqualia pharma | 402 |
| pfizer | 37 |
| askat | 8 |
| cj healthcare corporation | 8 |
| pfizer japan | 3 |
| pfizer products | 3 |
| asahi kasei pharma corporation | 2 |
| rakvalia farma ink. | 2 |
| requalia pharma | 2 |
| rqualia phamra | 1 |
2009
| raqualia pharma | 14 |
| pfizer | 7 |
| pfizer products | 3 |
| pfizer japan | 1 |
| rakvalia farma ink. | 1 |
| requalia pharma | 1 |
Raqualia Pharma
The top ten patent families are
|
Title of patent family (most common patent title) |
Family members |
Filing year |
|---|---|---|
| selective ep4 receptor agonistic substance for treatment of cancer | 27 | 2009 |
| acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal… 🛈 | 23 | 2009 |
| a 5-ht4 receptor agonist as a prokinetic agent | 23 | 2011 |
| pyrrolopyridinone derivatives as ttx-s blockers | 22 | 2012 |
| polymorph forms | 22 | 2012 |
| polymorph forms | 21 | 2013 |
| use of ep4 receptor antagonists in the treatment of il-23 mediated diseases | 21 | 2010 |
| pyrazolopyridine derivatives as ttx-s blockers | 21 | 2012 |
| benzimidazolone compounds having 5-ht4 receptor agonistic activity | 21 | 2003 |
| novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity | 20 | 2008 |